REG - Surgical Innovations - Directorate Change

Surgical InnovationsAnnouncement

05/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231205:nRSE6219Va&default-theme=true

RNS Number : 6219V  Surgical Innovations Group PLC  05 December 2023

Surgical Innovations Group Plc

 ("Surgical Innovations", the "Company" or the "Group")

 

 

Directorate Change

 

Surgical Innovations appoints Keyvan Djamarani as Independent Non-executive
Director

Nigel Rogers steps down, concluding the Board succession plan

 

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and
distributor of innovative technology for minimally invasive surgery, announces
that Keyvan Djamarani has been appointed as Independent Non-executive Director
with immediate effect. This follows an extensive process led by an independent
head-hunter. At the same time Nigel Rogers, who previously served time as
Chair of the Company, will step down from the Board.

 

Keyvan has over 30 years' relevant experience, holding numerous leadership
roles in product development within manufacturing organisations covering
medical and pharmaceutical drug delivery devices. He has a track record of
delivering increased sales, profitability and business critical programmes and
projects. Most recently he spent over nine years as Managing Director/Business
President at Bespak Europe, a medical and pharmaceutical drug delivery devices
business. Keyvan began his career at Unilever working in their Detergents and
Personal Products Divisions prior to joining Bespak. At Bespak, Keyvan held
several roles across their European and North American divisions. Within this
period, from 2002 to 2005, Keyvan was General Manager and President of Bespak
Inc. and from 2010 to 2013, Keyvan became CEO of King Systems, an airways
management business, encompassing design, development and manufacture of
airway management products. Keyvan was most recently a Non-executive Director
of CEME Ltd, a not-for-profit business enterprise operating on a 19-acre
campus, home to over 100 engineering, technology and training businesses - a
role he held for over 16 years.

 

As announced on 22 May 2023, Nigel Rogers will step down from the Board with
immediate effect, concluding the final part of the planned Board succession
process. Nigel joined the Board in 2015, bringing stability to the Company at
a critical time.

 

Chair of the Company, Jonathan Glenn, commented: "I would like to thank Nigel
for the dedicated service he provided to Surgical Innovations over his
eight-year tenure, bringing the Company safely through a number of significant
challenges including the pandemic. His experience proved invaluable and his
insight has always been appreciated by the Board and management.

"I am also delighted to welcome Keyvan to the Board. He has an excellent track
record in the medical device sector and brings with him a broad and relevant
skillset. His extensive operational experience will provide a wealth of
expertise to the Board, affording valuable insight into the challenges of
manufacturing as the Company undertakes a major efficiency drive to improve
margins."

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules for Companies:

 

Dr Keyvan Mehdi Djamarani (aged 62) is currently, or has during the past five
years, been a director of the following companies:

 

 Current directorships or partnerships  Previous directorships or partnerships
 ·    n/a                               ·    Centre for Engineering and Manufacturing Excellence Ltd

                                        ·    Bespak Europe Limited

                                        ·    Integrated Aluminium Components Limited

                                        ·    The Medical House Group Limited

                                        ·    The Medical House Limited

                                        ·    The Medical House Products Limited

                                        ·    Medical House (ASI) Limited

                                        ·    Hyperlyser Limited

 

Save as set out in this announcement there are no further details to be
disclosed in accordance with Rule 17 and Schedule Two Paragraph (g) of the AIM
Rule for Companies.

 

 

For further information please contact:

 

 Surgical Innovations Group plc                                                www sigroupplc com (http://www.sigroupplc.com/)
 David Marsh, CEO                                                              Tel: 0113 230 7597
 Charmaine Day, CFO

 Singer Capital Markets (Nominated Adviser & Broker)                                                     Tel: 020 7496 3000
 Aubrey Powell / Oliver Platts

 Walbrook PR (Financial PR & Investor Relations)      Tel: 020 7933 8780 or si@walbrookpr.com (mailto:si@walbrookpr.com)
 Paul McManus / Charlotte Edgar                                                Mob: 07980 541 893 / 07584 391 303

 

 

About Surgical Innovations Group plc

The Group specialises in the design, manufacture, sale and distribution of
innovative, high quality medical products, primarily for use in minimally
invasive surgery. Our product and business development is guided and supported
by a key group of nationally and internationally renowned surgeons across the
spectrum of minimally invasive surgical activity.

 

We design and manufacture and source our branded port access systems, surgical
instruments and retraction devices which are sold directly in the UK home
market through our subsidiary, Elemental Healthcare, and exported widely
through a global network of trusted distribution partners. Many of our
products in this field are based on a "resposable" concept, in which the
products are part reusable, part disposable, offering a high quality and
environmentally responsible solution at a cost that is competitive against
fully disposable alternatives.

 

Elemental also has exclusive UK distribution for a select group of specialist
products employed in laparoscopy, bariatric and metabolic surgery, hernia
repair and breast reconstruction.

 

In addition, we design and develop medical devices for carefully selected OEM
partners and have also collaborated with a major UK industrial partner to
provide precision engineering solutions to complex problems outside the
medical arena.

 

We aim for our brands to be recognised and respected by healthcare
professionals in all major geographical markets in which we operate and
provide by development, partnership or acquisition a broad portfolio of cost
effective, procedure specific surgical instruments and implantable devices
that offer reliable solutions to genuine clinical needs in the operating
theatre environment.

 

Further information

Further details of the Group's businesses and products are available on the
following websites:

www.sigroupplc.com (http://www.sigroupplc.com)

www.surginno.com (http://www.surginno.com)

www.elementalhealthcare.co.uk (http://www.elementalhealthcare.co.uk)

 

To receive regular updates by email, please contact si@walbrookpr.com
(mailto:si@walbrookpr.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPGUUPUPWGMC